On December 29, the reporter learned from the Shenzhen Municipal Market Supervision Bureau that recently, Mapasisavir capsules, a Class 1 innovative drug developed by a pharmaceutical company in Shenzhen, were approved for marketing by the State Drug Administration. Mapasisavir capsules are a novel cap-dependent nucleic acid endonuclease inhibitor that can effectively block the replication and spread of the influenza virus. It has the characteristics of rapid efficacy, long inhibition of the virus, good tolerability, and oral administration is not affected by food. It brings new treatment options for adolescents aged 12 and above and adult influenza A and B patients. Compared with mainstream anti-influenza drugs already on the market, mapacisavir capsules have a long-term advantage. A single oral administration can complete the full course of treatment. The launch of this Class 1 innovative drug mapasisavir capsules is the result of the Shenzhen Market Supervision Administration's full promotion through the creation of a quick-link service mechanism for the development of the biomedical industry, the establishment of a special service class, and full guidance services in R&D, registration, and licensing. (Shenzhen Special Administrative Region Newspaper)

On December 29, the reporter learned from the Shenzhen Municipal Market Supervision Bureau that recently, Mapasisavir capsules, a Class 1 innovative drug developed by a pharmaceutical company in Shenzhen, were approved for marketing by the State Drug Administration. Mapasisavir capsules are a novel cap-dependent nucleic acid endonuclease inhibitor that can effectively block the replication and spread of the influenza virus. It has the characteristics of rapid efficacy, long inhibition of the virus, good tolerability, and oral administration is not affected by food. It brings new treatment options for adolescents aged 12 and above and adult influenza A and B patients. Compared with mainstream anti-influenza drugs already on the market, mapacisavir capsules have a long-term advantage. A single oral administration can complete the full course of treatment. The launch of this Class 1 innovative drug mapasisavir capsules is the result of the Shenzhen Market Supervision Administration's full promotion through the creation of a quick-link service mechanism for the development of the biomedical industry, the establishment of a special service class, and full guidance services in R&D, registration, and licensing. (Shenzhen Special Administrative Region Newspaper)